HIGHLIGHTS
- who: Chuangzhou Rao from the Institute (IRCCS), Italy University of Milano-Bicocca, Italy have published the research: Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation, in the Journal: (JOURNAL)
- what: The authors report two cases in which genetic testing with biopsies before and after disease progression on crizotinib identified ALK C1156F as an acquired resistant mutation.
SUMMARY
Tyrosine kinase inhibitors (TKIs) inhibiting the kinase activity of anaplastic lymphoma kinase (ALK) have become the standard-of-care for advanced non-small cell . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.